SCHEMBL4073443

SCHEMBL4073443

CC(C)(C)c1ccc(S(=O)(=O)CC#N)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.51
LMNA P02545 4/20 0.51
HPGD P15428 3/20 0.51
MAPT P10636 3/20 0.51
KMT2A Q03164 3/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
TSHR P16473 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
MEN1 O00255 2/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2C19 P33261 2/20 0.51
GMNN O75496 1/20 0.51
DRD1 P21728 1/20 0.51
DRD3 P35462 1/20 0.51
CCR2 P41597 1/20 0.51
BLM P54132 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15299574 0.86 RORC (0.40) ALDH1A1LMNAHPGDMAPTKMT2A
SCHEMBL7967599 0.81 MMP1 (0.47) MAPTCA1CA2LGMN
SCHEMBL4074745 0.79 ENPP2 (0.45) SMN1; SMN2TP53
SCHEMBL1169954 0.79 ALDH1A1 (0.55) ALDH1A1LMNAHPGDMAPTKMT2A
SCHEMBL9906397 0.78 ALDH1A1 (0.59) ALDH1A1LMNAHPGDMAPTKMT2A
SCHEMBL3256579 0.78 ALDH1A1 (0.59) ALDH1A1LMNAHPGDMAPTKMT2A
SCHEMBL3247012 0.76 ALDH1A1 (0.50) ALDH1A1KMT2ANPC1MEN1CYP3A4
SCHEMBL7118736 0.76 CA2 (0.52) ALDH1A1HPGDMAPTKMT2ATDP1
SCHEMBL4079205 0.75 F2 (0.41) MAPTTP53CA1CA2
SCHEMBL22057007 0.75 MAPT (0.53) ALDH1A1MAPTCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE30303-E 1-AMINO-4-CYANO-1,3-BUTADIENE COMPOUNDS EASTMAN KODAK COMPANY (US) 1980-06-10 US claimed
US-10947203-B2 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor ST. JUDE CHILDREN'S RSEARCH HOSPITAL (US) 2021-03-16 US disclosed
US-10947203-B2 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor ST. JUDE CHILDREN'S RSEARCH HOSPITAL (US) 2021-03-16 US disclosed
US-20200071281-A1 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR ST JUDE CHILDREN?S RES HOSPITAL (US) 2020-03-05 US disclosed
US-20200071281-A1 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR ST JUDE CHILDREN?S RES HOSPITAL (US) 2020-03-05 US disclosed
US-10550091-B2 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2020-02-04 US disclosed
US-10550091-B2 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2020-02-04 US disclosed
US-20190077770-A1 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR ST. JUDE CHILDREN'S RSEARCH HOSPITAL 2019-03-14 US disclosed
US-20190077770-A1 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR ST. JUDE CHILDREN'S RSEARCH HOSPITAL 2019-03-14 US disclosed
WO-2017165139-A1 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2017-09-28 WO disclosed
US-20060128662-A1 Novel compounds for treatment of obesity NOVO NORDISK A/S (DK) 2006-06-15 US disclosed
EP-1625112-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2006-02-15 EP disclosed
US-6875771-B2 Pyridopyrimidine derivatives as 5-HT6 antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-05 US disclosed
WO-2004101505-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2004-11-25 WO disclosed
US-20040019064-A1 Pyridopyrimidine derivatives as 5-HT6 antagonists WU YONG-JIN (US) 2004-01-29 US disclosed
EP-0941994-B1 Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity HOFFMANN LA ROCHE (CH) 2003-05-14 EP disclosed
US-6194410-B1 ANTISEROTONINE AGENTS; NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS HOFFMAN-LA ROCHE INC. 2001-02-27 US disclosed
EP-0941994-A1 Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity F. HOFFMANN-LA ROCHE AG (CH) 1999-09-15 EP disclosed
US-4172944-A Water insoluble styryl dyestuffs having hetero-aryl methylene substituent BAYER AKTIENGESELLSCHAFT (DE) 1979-10-30 US disclosed
US-4016191-A WATER INSOLUBLE; LIGHTFASTNESS BAYER AKTIENGESELLSCHAFT (DT) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10550091-B2 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor NR5A1, CYP11B1, CYP3A5 ALDH1A1 2290/4885LMNA 4444/4885HPGD 896/4885
US-20200071281-A1 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR NR5A1, CYP11B1, CYP3A5 ALDH1A1 2290/4885LMNA 4444/4885HPGD 896/4885
US-10947203-B2 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor NR5A1, CYP11B1, CYP3A5 ALDH1A1 1881/4885LMNA 4350/4885HPGD 703/4885
US-20040019064-A1 Pyridopyrimidine derivatives as 5-HT6 antagonists HTR6, HTR4, HTR1A ALDH1A1 3386/4885LMNA 3345/4885HPGD 1330/4885
US-20190077770-A1 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR NR5A1, CYP11B1, CYP3A5 ALDH1A1 2290/4885LMNA 4444/4885HPGD 896/4885
US-20060128662-A1 Novel compounds for treatment of obesity GPR119, FABP4, HSD17B4 ALDH1A1 66/4885LMNA 3584/4885HPGD 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.